1

Corporate IntroductionAugust 2007

2

Safe Harbor Statement

Statements contained in this presentation may be forward-looking statements within themeaning of the Private Securities Litigation Reform Act of 1995 involving known andunknown risks, delays, and uncertainties that may cause the our actual results orperformance to differ materially from those expressed or implied by these forward-lookingstatements. These risks, delays, and uncertainties include, but are not limited to: risksassociated with the uncertainty of future financial results, our reliance on our sole supplier,the limited diversification of our product offerings, additional financing requirements,development of new products, government approval processes, the impact of competitiveproducts or pricing, technological changes, the effect of economic conditions and otheruncertainties detailed in the Company's filings with the Securities and ExchangeCommission. The Company undertakes no obligation to update any forward-lookingstatements.

3

About RxElite

RxElite (OTCBB: SOUT) Total Shares Outstanding: 83.7 Million / Float: 16.5 Million Market Capitalization: $121.4 Million1

Insider Ownership: 25.8%

RxElite Holdings, Inc., founded in 2000, develops, manufactures, and markets genericprescription drug products in specialty generic markets. These markets include products inthe areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs,ophthalmics, and injectable drugs), and transdermal patch products.

Recently Closed a $19.6M Financing

1. As of August 14, 2007

4

Business Strategy / Model

Specialty Focus –Expertise and investments in specialty products, characterized by» High barriers to entry,» Limited competition,

» Good margin opportunities;

Low Cost Excellence» Be low cost producer

» Maintain low cost operations with scalable infrastructure;

Leverage Distribution Strength» Vendor to 46 of top 50 US generic buyers

» Approved vendor contracts with all 8 hospital GPOs

Unparallel Service - 100% deliverability» 74 months of uninterrupted supply –100% fulfillment

5

Specialty Generic Contains Attractive Segments

IR Oral SolidsCreams/OintmentsCR Oral SolidsOral Suspensions

AerosolsCytotoxicsOphthalmicsInjectables (in glass)

Injectables (inplastic)Transdermals

Schedule II ProductsBiogenericsAnesthetic GasesIntranasalsHormonals

Low HighMedium

Number of Competitors

Hig

hLo

wM

ediu

m

Bar

rier

toM

arke

tE

ntr

y

(1) Injectables in plastic

6

Leading HomecareCompanies

•Lincare•Apria•ChemRx

Major DirectStocking Chains

•Wal-Mart•Walgreens•Hannaford Bros.

All RegionalWholesalers

•ANDA•Harvard Drugs•Kinray

All 3 NationalWholesalers

•McKesson•Cardinal•AmerisourceBergen

Product Distribution: 46 of the top 50 US Generic Buyers

Market Credibility = National Distribution Strength

It takes longer to establish market credibilitythan to attain an ANDA

Distribution Strength

7

Superior Execution

RxElite's goal: To be the generic buyer's "vendor of choice" for each of their products byproviding the highest quality products at the best prices, with 100% deliverability;

Quality –All RxElite’s products meet current FDA standards;

Price –Delivering the best value to customers by combining select manufacturingtechnologies and proprietary processes, with low cost distribution methods;

Deliverability –RxElite has maintained a track record of 100% order fulfillment rate forover 74 months of uninterrupted supply;

8

Business Opportunity

Market Size: Total addressable market from pipeline products exceed $2 Billion» Sevoflurane is a $400 Million market in the US, with limited competitors;

Market Growth: US Sevoflurane market growth is forecasted to be 11%-15% year overyear (in volume);

Growth Strategy: Organic growth through» A pipeline of more than ten specialty generic drugs with high barriers to entry;» Partnering agreements with low cost generic drug producers

− Further leverage RxElite’s existing distribution network,− Combine to launch new products beginning in 2008

Scalability & Margins» Scalable to increase business several times its current size without much increase

in fixed costs,» Potential for exponential increase in profitability as new products launch;

9

Competitive Advantage

Specialty product expertise» RxElite has a strong base in Blow Fill Seal (“BFS”) sterile liquid dose products,

» Expertise in other specialty areas through partnerships with leading companies in thedevelopment and manufacturing of anesthetic gases and transdermal patch products;

Uniquely positioned» Specialty products pipeline and partnership agreements with industry leaders;

» RxElite has robust marketing channels

» Well-developed sales and supplier relationships,

Strong product pipeline» Three Abbreviated New Drug Applications (ANDA) approved,» Over 10 ANDAs in various stages of development,

» Blockbuster generics through partnerships with low cost industry players;

Senior management» Experienced and understands the market,

» Great credibility with the market and its commercial partners;

10

Competitors

Competitors:

» Successfully competed with large industry players such as Dey Labs, IVAX (now part of Teva),Alpharma (now part of Actavis), and Warrick (generic subsidiary of Schering-Plough),

» Current competitors include Abbott and Baxter for RxElite’s recently launched Sevoflurane,

» Baxter and Hospira for other anesthetic gases;

Barriers to Additional Competition:

» Manufacturing process patents,

» Limited manufacturing capacity,

» Long lead times for new industry capacity to come online,

» Products that require unique expertise &/or lengthy approval times;

11

Risk

Limited product portfolio,

Depending on a single, large market product, for the next 12 months;

Risk Mitigation

» Sevoflurane has few competitors, and a $400 M market that is growing between 11 to 15% peryear,

» Successfully competing by

− Combining a highly competitive value, with flexibility, response, and service

» Strategic partners and ongoing corporate development efforts will continually diversify portfolio;

12

RxElite’s Future

Key Revenue Drivers

» 2007-2008: Anesthetic Gases

» 2009-2010: Partnerships Products

» 2010 and Beyond: Sterile Liquid Products

Anticipated Product Filings» 2007 –2008: 3 to 5 ANDA filings

Capabilities Expansion» Specialty Product Development and Sterile Manufacturing

13

Strategic Partners

Minrad International - exclusive manufacturing partner for anesthetic gas products

» Isoflurane

» Enflurane

» Sevoflurane

» Desflurane –Expected 2008/2009

Alkem Laboratories and Stason Pharmaceuticals exclusive manufacturing partner fororal solid products;

Core Tech Solutions is our exclusive manufacturing partner for a portfolio oftransdermal patch products;

14

8 Major GPO’s Control >90% of Hospital Purchasing

Novation; 24%

Premier; 20%

MedAssets/HSCA; 18%

Amerinet; 10%

Broadlane; 12%

HPG/Consorta; 12%

Cardinal; 3%

PACT; 1%

RxElite has approved vendor contracts with all 8 GPO’s RxEliteis the Sole Source Vendor to HPG/Consorta for Isoflurane and Enflurane

15

Sevoflurane –2007 Opportunity

FDA-Approved in May 2007

US Market: $400M» Market growing 11% - 15% per year (in units),

» Attractive competitive landscape with only 2 competitors (Abbott/Baxter);

16

Market Strategies

Focus where Abbott and Baxter are not

» Ambulatory/Outpatient surgery centers

− Highly defensible market share

− Vaporizer ownership

− Attractive pricing

» IDNs and Tier 2 GPOs

» Primary GPOs

» Experienced sales force:

− Value-added selling with focus on service

17

Desflurane –2008 / 2009 Opportunity

FDA-Approval expected in 2008 / 2009

US Market: $200M+» Attractive competitive landscape with 1 competitor until 2011 due to patent

conditions» Continues to be branded with growing market» Barriers to entry and profitable niche

18

$0

$5 000 000

$10 000 000

$15 000 000

$20 000 000

$25 000 000

$30 000 000

2001

2002

2003

2005

2006

RxElite Sales Performance (in US Dollars)

100% service deliverability withno backorders for over

6 years

Decrease of sales from 2005 to 2006reflects the divestiture of two productlines, Albuterol 0.083% and Ipratropium0.02%

Expect forecast sales to EXCEEDhistoric high following generic approvaland launch of Sevoflurane

19

Staged Growth and Cash Flows

Partnering Opportunities andPlatform Leverage

Vertical Integration andNew Products

• Minrad / Desflurane

• Sterile liquidsproducts

• Other specialtygenerics

2007 - 2008 2009 - 2011

• Minrad /Sevoflurane

• Stason• Alkem Labs

Market Credibility andDistribution leverage

• Albuterol Sulfate

• Ipratropium Bromide• Isoflurane• Enflurane

2001 - 2006

Stage I Stage II Stage III

OperatingMargins 5 - 10% 10 - 30%< 5%

20

Product Launches and Addressable Markets

Addressable Market

2007 2008 2009 2010 2011

$411 M$591 M

$1,836 M

$400M

$180M

$1,245M

$11M

$2,153 M

$317M

$2,494 M$341M

21

Specialty focus andpartnership growth oriented

Sterile liquids franchise

Recently completed FDA –approved sterile liquidsfacility

$622.5$635.0-$12.4/$-16.4

$52.4Akorn(AKRX)

Anesthetic gas partner

Rx Elite representssignificant portion offorecasted revenues

Near term prospects andUS economics similar

Producing Sevoflurane

$228.2$232.6-$9.32 / -$9.4

$18.4Minrad (BUF)

CommentsEnterprise

Value(M)

MarketCap(M)

EBITDA/Net

Income(M)

Sales(M)

Company

Public Comparables

1. Market Cap Values as of 8/15/2007

22

Key Management

Daniel Chen, Chairman & CEO - 2003Cendian Pharmaceuticals, Lifespan Biosciences, Astrazeneca, GSK, ALARIS Medical Systems, A.T.

Kearney & Merrill Lynch

Jonathan Houssian, President, Secretary, and Director - founderSISBRO LLC, Americare / Ashley Manor Care, TechHealth, and Everfill LLC, and D.A. Davidson

Earl Sullivan, EVP Operations - 2002Express-Med, Inc., Green Mountain Energy, and Metropane, Inc.

Patrick Poisson, VP Sterile Operations - 2007Cardinal Health, Genentech

Ric Tener, VP Administration - 2001BioBoost, Inc, C.F. Childs & Co., Eden Housing & Eden Social Services Inc., New York Health and

Hospital Corporation, and Blue Cross of Northern California

Key Sales Team MembersASC/Hospital - Steve Anderson (Guilford)

»Chad May (Abbott, Endo) , Kevin Dycus (Baxter), Andrew Horrocks (J&J), Tom Lennox (Endo)Wholesaler/Distributor/Retail Chains

»T Slaven (2001), Brad McElliott (2002)

23

RxElite Board Members

Mark Auerbach –Director»He was a director at Par pharmaceuticals (NYSE:PRX) from 1990 to 2006 with his last position as

its executive chairman of the board. During this period Par grew from a young generic drugscompany to over $500M in sales

Peter Williams –Director»He served on the board at Par Pharmaceuticals beginning in 2003. Mr. Williams served on the

board of the New York based Special Situations Fund, where he is Chairman of the IndependentGeneral Partners; and on the International Advisory Committee of RWE/Thames Water.

Daniel Chen –Chairman & CEO»RxElite Management Director

Jonathan Houssian –President»RxElite Management Director

24

Reasons to Invest

Specialty expertise in attractive markets» Sevoflurane has a generic market of $400M

Strong pipeline and solid distribution platform with track record of superior execution

Key partnerships in place, with new products launching in 2008

Investment in high value, sterile manufacturing capacity

Experienced management team focused on growth, quality, and cost

Attractive valuation relative to public comps

25

Questions